During the past decade, Institut Coeur-Poumon, CHU conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institut Coeur-Poumon, CHU" #1 sponsor was "University Hospital, Lille" with 4 trials, followed by "Janssen Research & Development, LLC" with 3 trials sponsored, "Amgen" with 2 trials sponsored, "Vertex Pharmaceuticals Incorporated" with 2 trials sponsored and "Assistance Publique - Hôpitaux de Paris" with 2 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institut Coeur-Poumon, CHU" #1 collaborator was "Biotronik France" with 1 trials as a collaborator, "Boehringer Ingelheim" with 1 trials as a collaborator, "Canadian Institutes of Health Research (CIHR)" with 1 trials as a collaborator, "Fédération Française de Cardiologie" with 1 trials as a collaborator and "INSERM U1189 ONCOTHAI" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Institut Coeur-Poumon, CHU" are "Carcinoma, Non-Small-Cell Lung" (2 trials), "Cystic Fibrosis" (2 trials), "Heart Failure" (2 trials), "Advanced or Metastatic Non-small Cell Lung Cancer" (1 trials) and "Aortic Valve Insufficiency" (1 trials). Many other conditions were trialed in "Institut Coeur-Poumon, CHU" in a lesser frequency.

Most popular intervention types in "Institut Coeur-Poumon, CHU" are "Drug" (9 trials), "Other" (5 trials), "Device" (2 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Amivantamab" (2 trials), "ELX/TEZ/IVA" (2 trials), "IVA" (2 trials) and "Lazertinib" (2 trials). Other intervention names were less common.

The vast majority of trials in "Institut Coeur-Poumon, CHU" are 14 trials for "All" genders.

Currently, there are NaN active trials in "Institut Coeur-Poumon, CHU". undefined are not yet recruiting, 8 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Institut Coeur-Poumon, CHU, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Institut Coeur-Poumon, CHU, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 4 trials that are defined as “Not Applicable".